Lutz Halle, Popowski Kristen D, Dinh Phuong-Uyen C, Cheng Ke
Department of Molecular Biomedical Sciences North Carolina State University Raleigh NC 27607 USA.
Comparative Medicine Institute North Carolina State University Raleigh NC 27607 USA.
Adv Nanobiomed Res. 2021 Mar;1(3):2000063. doi: 10.1002/anbr.202000063. Epub 2021 Jan 18.
New infectious diseases are making themselves known as the human population grows, expands into new regions, and becomes more dense, increasing contact with each other and animal populations. Ease of travel has also increased infectious disease transmission and has now culminated into a global pandemic. The emergence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 has already infected over 83.7 million people and caused over 1.8 million deaths. While there have been vaccine candidates produced and supportive care implemented, the world is impatiently waiting for a commercially approved vaccine and treatment for the coronavirus disease of 2019 (COVID-19). The different vaccine types investigated for the prevention of COVID-19 all have great promise but face safety obstacles that must be first addressed. Some vaccine candidates of key interest are whole inactivated viruses, adeno-associated viruses, virus-like particles, and lipid nanoparticles. This review examines nanobiomedical techniques for combatting COVID-19 in terms of vaccines and therapeutics.
随着人口增长、向新区域扩张并变得更加密集,人们之间以及与动物种群的接触增多,新的传染病不断出现。便捷的交通也增加了传染病的传播,如今已演变成一场全球大流行。2019年12月新型冠状病毒严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的出现,已经感染了超过8370万人,并导致超过180万人死亡。虽然已经有了候选疫苗并实施了支持性治疗,但全世界都在急切地等待2019冠状病毒病(COVID-19)的商业批准疫苗和治疗方法。为预防COVID-19而研究的不同类型疫苗都很有前景,但都面临必须首先解决的安全障碍。一些备受关注的候选疫苗包括全灭活病毒、腺相关病毒、病毒样颗粒和脂质纳米颗粒。本文综述了在疫苗和治疗方面对抗COVID-19的纳米生物医学技术。